Inluriyo vs Quzyttir
A plain-English comparison of two immunology drugs that may be accessible via NPP.
Side-by-side
| Inluriyo | Quzyttir | |
|---|---|---|
| Generic name | imlunestrant | cetirizine hydrochloride (IV injection) |
| Manufacturer | Eli Lilly and Company | TerSera Therapeutics |
| Modality | Oral selective estrogen receptor degrader / SERD (400 mg once daily) | IV histamine H1 receptor antagonist (1-2 minute push) |
| Indication | Oncology (ER+/HER2- metastatic breast cancer) | Allergy / urticaria |
| FDA approval | September 25, 2025 | October 4, 2019 |
When physicians choose Inluriyo
Inluriyo is typically selected when its mechanism and labeled indication fit the disease subtype. It is manufactured by Eli Lilly and Company and represents an Oral selective estrogen receptor degrader / SERD (400 mg once daily) option in Oncology (ER+/HER2- metastatic breast cancer).
When physicians choose Quzyttir
Quzyttir is typically selected when its mechanism aligns better with disease sub-type, prior therapy failure, or safety profile. It is manufactured by TerSera Therapeutics and represents an IV histamine H1 receptor antagonist (1-2 minute push) option in Allergy / urticaria.
Both drugs - access via NPP
Both Inluriyo and Quzyttir can be accessed via NPP in most of our covered markets. Choice between them is a clinical decision for the treating physician.
Not medical advice
This comparison is information, not clinical guidance.
Request either drug
Safety, interactions, and handling
Drug interactions: Before dispatch, our clinical team reviews every patient's full medication list against published FDA drug-interaction data. If a significant interaction is identified, we notify the prescribing physician and hold shipment until an alternative dose or timing is confirmed.
Contraindications: This medication is not appropriate for every patient. Refer to the US FDA label for full contraindication list. Patients with active infection, pregnancy, known hypersensitivity, or specific organ-system comorbidities may be excluded. Prescribing-physician judgement applies.
Cold chain and storage: Biologics, monoclonals, and cell/gene therapies require validated cold-chain shipping (2-8°C) with continuous temperature monitoring. On arrival we document temperature logs; out-of-spec shipments are flagged and replaced.
Adverse event reporting: Any adverse event should be reported to both the local national regulator and to Reserve Meds's pharmacovigilance team at [email protected]. We forward serious events to the US manufacturer within 15 days per ICH E2D guidance.
Last medically reviewed: 2026-04-22 by AI Clinical Review Agent (see Trust & Compliance).